Preliminary Scientific Programme

Wednesday, 4 December 2024

8:00-10:00

Registration

10:00-10:15

Welcome, introduction and objectives
Ana Giménez-Arnau (Spain)
Torsten Zuberbier (Germany)
Marcus Maurer (Germany)

10:15-10:45

Keynote lecture I

Oral Presentation Session I: The aetiopathogenesis of urticaria

10:45-11:05

What’s new?

11:05-11:50

Oral Presentations

11:14-11:23

OP.002  Transcriptome analysis of experimentally-induced wheals in patients with cold urticaria
Nasser Mohammad-Porras (Spain)

11:23-11:32

OP.003 The significant changes in the gene expression of STAT3, IL-27, and IL-35 in patients with chronic spontaneous urticaria
Maryam Khoshkhui (Iran)

11:32-11:41

OP.004 The role of skin chemokines in the pathogenesis of CSU
Elias Toubi (Israel)

11:41-11:50

OP.005  Investigating endothelial dysfunction in chronic spontaneous urticaria
Katie Ridge (Ireland)

11:50-12:15

Coffee Break 

EMBRN Session: The biology of mast cells and basophils and their role in health and disease

12:15-12:20

Introduction

12:20-13:00

Science talk

13:15-14:00

Company-Sponsored Lunch Symposium

13:00-14:20

15:25-15:55

Lunch Break

Keynote lecture II

Oral Presentation Session II: Differential diagnosis, comorbidities, diagnostic approaches and biomarkers

14:20-14:40

What’s new?

14:40-15:55

Oral Presentations

14:49-14:58

OP.007  PREDICT-CU: Predicting time to clinical remission in chronic urticaria
Maria-Magdalena Balp (Switzerland)

14:58-15:07

OP.008  Remibrutinib inhibits mastcell and basophil activation in chronic urticaria independently of FcεR1 expression
Ana Giménez-Arnau (Spain)

14:07-15:16

OP.009  Urticaria in patients with suspected mast cell activation syndrome
Fabiana Nunes Oliveira (Brazil)

14:16-15:25

OP.010  In chronic spontaneous urticaria, fever, pain and malaise are common and linked to active and uncontrolled disease: Results from the Chronic Urticaria Registry (CURE)
Polina Pyatilova (Germany)

15:25-15:55

Keynote lecture II

15:55-16:20

Coffee Break 

Workshop

16:20-16:27

Introduction and overview over past UCARE Projects
Ana Giménez-Arnau (Spain) & Marcus Maurer (Germany)

16:27-17:03

Quick Presentations of current and upcoming UCARE Projects 
Project Leaders

17:03-17:13

Presentation of CURE and CRUSE Control
Yana Hackler, Karsten Weller & Sophia Neisinger (Germany)

17:13-17:20

Discussion, Questions and Wrap-up
Ana Giménez-Arnau (Spain) & Marcus Maurer (Germany)

Oral Presentation Session III: Urticaria treatments and predictors of response

16:20-16:40

What’s new?

16:40-17:25

Oral Presentations

17:49-17:58

OP.012 Long-term safety of remibrutinib in CSU patients: Phase 2b study
Ana Giménez-Arnau (Spain)

17:58-18:07

OP.013 Dupilumab Efficacy in Patients with Chronic Spontaneous Urticaria with Comorbidities
Marcus Maurer (Germany)

18:07-18:16

OP.014 Cold urticaria patients achieve complete response with 1.5 mg/kg barzolvolimab
Dorothea Terhorst-Molawi (USA)

18:16-18:25

OP.015 Elevated levels of soluble FcεRI as a biomarker of early and good response to omalizumab treatment in chronic spontaneous urticaria
Sherezade Moñino-Romero (Germany)

18:25-18:34

OP.016 Differences between pediatric and adult urticaria: patient characteristics, treatment response and indicators of response
Sinem Ornek Ozdemir (Turkey)

18:34-18:43

OP.017 Autoimmunity and low IgE in CSU: a prospective analysis
David Pesqué (Spain)

18:43-18:52

OP.018 Anti-TPO/total IgE ratio – biomarker for omalizumab response prediction in CSU
Rita Brás (Portugal)

17:25-18:10

18:10-18:15

19:00

Urticaria Quiz – Test your knowledge (and win a prize)

Closing Remarks

Scientific Dinner 

Thursday, 5 December 2024

07:15-08:30

Registration 

08:30-08:45

Welcome and summary day 1
Ana Giménez-Arnau (Spain)
Torsten Zuberbier (Germany)
Marcus Maurer (Germany)

Oral Presentation Session IV: Urticariological highlights

08:45-09:05

What’s new?

09:05-09:14

Oral Presentations

09:14-09:23

OP.020 Treatment with MRGPRX2 Antagonist EP262 Potently Inhibits Mast Cell Degranulation 
Veena Viswanath (USA)

09:23-09:32

OP.021 Remibrutinib improves CSU in patients with low or high IgE
Michihiro Hide (Japan)

09:32-09:41

OP.022 Anti-IL-23 treatment in patients with omalizumab-refractory chronic spontaneous urticaria – a case series
Hanna Bonnekoh (Germany)

09:41-09:50

OP.023 Omalizumab drug survival for chronic urticaria – the DruSO-CU UCARE study
Reineke Soegiharto (The Netherlands)

09:50-09:59

OP.024 CRUSE – What the first 100 days have taught us
Sophia Neisinger (Germany)

10:00-11:30

Poster Session and coffee

11:30-12:15

Interactive Case Journey 

11:50-13:00

Problems you like, solutions you’re looking for –
An interactive patient journey
Facilitators: Karoline Krause (Germany) & Frank Siebenhaar (Germany)

ACARE Session: Recurrent angioedema

12:15-13:00

Science Talk

14:35-14:48

Erythema marginatum as initial phase of an hereditary angioedema attack
Kinga Viktoria Kohalmi (Hungary)

14:48-15:01

Importance of the complement test in patients with angioedema taking  ACE inhibitor
Henriette Farkas (Hungary)

15:01-15:14

The use of anti-IgE therapy to define idiopathic non-histaminergic angioedema
Jason Fok (Australia)

15:14-15:27

Estrogen triggering non-hereditary Angioedema
Anete Grumach (Brazil)

15:27-15:40

ACARE projects and activities
Markus Magerl (Germany)

 13:00-14:20

Lunch break

  13:15-14:00

Company-Sponsored Lunch Symposium

Oral Presentation Session V: Emerging treatments of urticaria

14:20-14:40

What’s new?

14:40-15:34

Oral Presentations

 Industry Session

   15:34-16:04

Keynote lecture III

Thursday, 8 Decemeber 2022

07:30-08:15

Sponsored Breakfast Symposium
Type 2 Inflammation in CSU: Emerging Evidence and Implications

Available soon

If you need child care, please contact our professional congress organiser.

Impressions hybrid GUF 2022
Organisation
Professional Congress Organiser

Remember Management GmbH
Albrechtstr. 14 b, 10117 Berlin, Germany
Phone: +49 30 47 37 25 77
E-mail: guf@remember-management.de
www.remember-management.de

Join the 7th Consensus Conference too!